These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20967172)

  • 21. Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted.
    Gringeri A; Mannucci PM
    Blood; 2007 Oct; 110(8):3084; author reply 3085. PubMed ID: 17916754
    [No Abstract]   [Full Text] [Related]  

  • 22. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.
    Scharrer I; Ehrlich HJ
    Haemophilia; 2001 Jul; 7(4):346-8. PubMed ID: 11442637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. World registry on factor VIII inhibitor patients: why?
    Aledort LM
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):7-9. PubMed ID: 8480198
    [No Abstract]   [Full Text] [Related]  

  • 26. Comments on the development of inhibitor antibodies in patients using recombinant factor VIII concentrates.
    Brettler DB
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):45-6. PubMed ID: 1908128
    [No Abstract]   [Full Text] [Related]  

  • 27. Previously untreated patients and recombinant factor VIII concentrate studies.
    Pasi KJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
    Lusher JM
    Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
    [No Abstract]   [Full Text] [Related]  

  • 29. Factor VIII inhibitor developed in a 60-year-old patient with mild hemophilia A after surgery for colon cancer.
    Suzuki T; Arai M; Miyasaka S; Watanabe J; Sugimura D; Amano K; Yamagishi T; Kagawa K; Fukue H; Fukutake K
    Int J Hematol; 1995 Aug; 62(2):127-32. PubMed ID: 8590774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia.
    Werwitzke S; Tiede A; Stoll M; von Depka M
    J Thromb Haemost; 2004 Jan; 2(1):193-4. PubMed ID: 14717985
    [No Abstract]   [Full Text] [Related]  

  • 31. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 33. Immune tolerance in hemophilia and the treatment of hemophiliacs with an inhibitor. Proceedings of a meeting. Palermo, Italy, October 1999.
    Haematologica; 2000 Oct; 85(10 Suppl):1-116. PubMed ID: 11236744
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibitors in haemophilia: clinical aspects.
    Dimichele D; Rivard G; Hay C; Antunes S
    Haemophilia; 2004 Oct; 10 Suppl 4():140-5. PubMed ID: 15479387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful eradication of inhibitor of late recurrence and other high risk prognostic factors in a patient with severe haemophilia A.
    Ranta S; Koskinen S; Mäkipernaa A
    Haemophilia; 2011 Sep; 17(5):e833-4. PubMed ID: 21624011
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
    Franchini M; Lippi G
    Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Summary report of the First International Conference on inhibitors in haemophilia A.
    Lacroix-Desmazes S; Scott DW; Goudemand J; Van Den Berg M; Makris M; Van Velzen AS; Santagostino E; Lillicrap D; Rosendaal FR; Hilger A; Sauna ZE; Oldenburg J; Mantovani L; Mancuso ME; Kessler C; Hay CRM; Knoebl P; Di Minno G; Hoots K; Bok A; Brooker M; Buoso E; Mannucci PM; Peyvandi F
    Blood Transfus; 2017 Oct; 15(6):568-576. PubMed ID: 27893354
    [No Abstract]   [Full Text] [Related]  

  • 39. Anaphylaxis after treatment with recombinant factor VIII.
    Shopnick RI; Kazemi M; Brettler DB; Buckwalter C; Yang L; Bray G; Gomperts ED
    Transfusion; 1996 Apr; 36(4):358-61. PubMed ID: 8623140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.